- Home
- MAN vs XERS Comparison
MAN vs XERS Comparison
Compare MAN & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAN | XERS |
|---|---|---|
| Founded | 1948 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1988 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MAN | XERS |
|---|---|---|
| Price | $30.37 | $7.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $39.50 | $10.43 |
| AVG Volume (30 Days) | 836.7K | ★ 2.3M |
| Earning Date | 01-29-2026 | 03-02-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,643,700,000.00 | $266,137,000.00 |
| Revenue This Year | $1.15 | $44.77 |
| Revenue Next Year | $3.60 | $27.72 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 42.05 |
| 52 Week Low | $26.14 | $3.24 |
| 52 Week High | $63.35 | $10.08 |
Technical Indicators
Market Signals| Indicator | MAN | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 50.30 |
| Support Level | $28.83 | $7.25 |
| Resistance Level | $31.54 | $7.85 |
| Average True Range (ATR) | 1.17 | 0.34 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 53.25 | 37.46 |
Price Performance
Historical ComparisonAbout MAN ManpowerGroup
ManpowerGroup Inc. is engaged in providing workforce solutions and services. The company provides services that include Recruitment and Assessment, Upskilling, Reskilling, Training and Development, Career Management, Outsourcing, and Workforce Consulting. The reportable segments of the company are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others. The Staffing and Interim segment derives the maximum of the company's revenue. The company derives maximum geographical revenue from the Southern European region.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).